On the public citation graph
Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease
0 signed · 603 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jamainternmed.2016.9607openalex-snapshot
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1002/dmrr.2561openalex-snapshot
Benefits of exenatide on obesity and non‐alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes
inferredcites →https://doi.org/10.1002/hep.24558openalex-snapshot
Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12-month randomized, prospective, open- label trial
inferredcites →https://doi.org/10.1002/hep.28356openalex-snapshot
The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota
inferredcites →https://doi.org/10.1002/hep.28827openalex-snapshot
Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study
inferredcites →https://doi.org/10.1007/s00125-011-2446-4openalex-snapshot
Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials
inferredcites →https://doi.org/10.1007/s00125-018-4702-3openalex-snapshot
Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial
inferredcites →https://doi.org/10.1007/s00535-017-1364-8openalex-snapshot
Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials
inferredcites →https://doi.org/10.1007/s13300-017-0273-4openalex-snapshot
Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis
inferredcites →https://doi.org/10.1016/j.cgh.2018.04.042openalex-snapshot
Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1016/j.cmet.2011.11.004openalex-snapshot
Excessive Hepatic Mitochondrial TCA Cycle and Gluconeogenesis in Humans with Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1016/j.cmet.2015.04.004openalex-snapshot
Adaptation of Hepatic Mitochondrial Function in Humans with Non-Alcoholic Fatty Liver Is Lost in Steatohepatitis
inferredcites →https://doi.org/10.1016/j.jhep.2015.08.038openalex-snapshot
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
inferredcites →https://doi.org/10.1016/j.jhep.2015.11.004openalex-snapshot
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
inferredcites →https://doi.org/10.1016/j.jhep.2016.04.021openalex-snapshot
Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial
inferredcites →https://doi.org/10.1016/j.jhepr.2019.07.002openalex-snapshot
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
inferredcites →https://doi.org/10.1016/s0026-895x(24)12240-7openalex-snapshot
Tumor Necrosis Factor-α-Induced Cyclooxygenase-2 Expression via Sequential Activation of Ceramide-Dependent Mitogen-Activated Protein Kinases, and IκB Kinase 1/2 in Human Alveolar Epithelial Cells
inferredcites →https://doi.org/10.1016/s0140-6736(14)61933-4openalex-snapshot
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
inferredcites →https://doi.org/10.1016/s0140-6736(15)00803-xopenalex-snapshot
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
inferredcites →https://doi.org/10.1016/s0140-6736(18)30474-4openalex-snapshot
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
inferredcites →https://doi.org/10.1016/s0739-5930(09)79298-0openalex-snapshot
Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1016/s1542-3565(04)00457-4openalex-snapshot
A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis
inferredcites →https://doi.org/10.1021/acs.jmedchem.7b00907openalex-snapshot
Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
inferredcites →https://doi.org/10.1038/nm.3082openalex-snapshot
An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice
inferredcites →https://doi.org/10.1038/s41387-020-0114-9openalex-snapshot
Reducing endogenous insulin is linked with protection against hepatic steatosis in mice
inferredcites →https://doi.org/10.1038/srep05832openalex-snapshot
Association between serum free fatty acid levels and nonalcoholic fatty liver disease: a cross-sectional study
inferredcites →https://doi.org/10.1053/j.gastro.2008.06.047openalex-snapshot
Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1053/j.gastro.2013.05.042openalex-snapshot
Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1053/j.gastro.2015.04.043openalex-snapshot
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1053/j.gastro.2016.01.038openalex-snapshot
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
inferredcites →https://doi.org/10.1056/nejmoa060326openalex-snapshot
A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1056/nejmoa0907929openalex-snapshot
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1056/nejmoa1603827openalex-snapshot
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1611925openalex-snapshot
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
inferredcites →https://doi.org/10.1100/2012/496453openalex-snapshot
The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
inferredcites →https://doi.org/10.1111/apt.12149openalex-snapshot
Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta‐analysis of the LEAD program
inferredcites →https://doi.org/10.1111/dom.13061openalex-snapshot
Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non‐alcoholic fatty liver disease: A prospective randomized controlled pilot study
inferredcites →https://doi.org/10.1111/hepr.12351openalex-snapshot
Pilot study of liraglutide effects in non‐alcoholic steatohepatitis and non‐alcoholic fatty liver disease with glucose intolerance in J apanese patients ( LEAN ‐ J )
inferredcites →https://doi.org/10.1111/j.1365-2249.2011.04511.xopenalex-snapshot
Oral administration of immunoglobulin G-enhanced colostrum alleviates insulin resistance and liver injury and is associated with alterations in natural killer T cells
inferredcites →https://doi.org/10.1111/jdv.12814openalex-snapshot
Anti‐ TNF ‐α therapy improves insulin sensitivity in non‐diabetic patients with psoriasis: a 6‐month prospective study
inferredcites →https://doi.org/10.1126/science.7678183openalex-snapshot
Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
inferredcites →https://doi.org/10.1155/2019/8748459openalex-snapshot
Association between Hemoglobin Glycation Index and NAFLD in Chinese Nondiabetic Individuals
inferredcites →https://doi.org/10.1172/jci41636openalex-snapshot
The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans
inferredcites →https://doi.org/10.1172/jci86013openalex-snapshot
Insulin receptor Thr1160 phosphorylation mediates lipid-induced hepatic insulin resistance
inferredcites →https://doi.org/10.1194/jlr.r024794openalex-snapshot
Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease
inferredcites →https://doi.org/10.1210/jc.2011-2260openalex-snapshot
Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
inferredcites →https://doi.org/10.1210/jc.2016-3237openalex-snapshot
Pioglitazone and Risk for Bone Fracture: Safety Data from a Randomized Clinical Trial
inferredcites →https://doi.org/10.1590/s0004-27302013000900005openalex-snapshot
Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease
inferredcites →https://doi.org/10.2147/jir.s35227openalex-snapshot
Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I/II clinical trial in NASH
inferredcites →https://doi.org/10.2337/dc06-2247openalex-snapshot
Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients
inferredcites →https://doi.org/10.2337/dc15-0642openalex-snapshot
Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport
inferredcites →https://doi.org/10.2337/dc17-0078openalex-snapshot
Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes
inferredcites →https://doi.org/10.2337/dc17-0518openalex-snapshot
Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial
inferredcites →https://doi.org/10.2337/dc17-1902openalex-snapshot
Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis
inferredcites →https://doi.org/10.2337/dc18-0165openalex-snapshot
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
inferredcites →https://doi.org/10.2337/diab.45.7.881openalex-snapshot
Effects of an Engineered Human Anti–TNF-α Antibody (CDP571) on Insulin Sensitivity and Glycemic Control in Patients With NIDDM
inferredcites →https://doi.org/10.3748/wjg.v19.i40.6911openalex-snapshot
Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis
inferredcites →https://doi.org/10.3748/wjg.v23.i1.141openalex-snapshot
Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial
inferredcites →https://doi.org/10.3748/wjg.v26.i18.2203openalex-snapshot
Folic acid attenuates high-fat diet-induced steatohepatitis via deacetylase SIRT1-dependent restoration of PPARα
inferredcites →https://doi.org/10.3892/br.2012.18openalex-snapshot
Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis
inferredcites →https://doi.org/10.5754/hge11263openalex-snapshot
Sitagliptin as a Novel Treatment Agent for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus
inferredcites →https://doi.org/10.7326/m15-1774openalex-snapshot
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.5114053openalex-extracted
Natural Products as Modulators of Nrf2 Signaling Pathway: Potential Therapeutic Agents for Metabolic Associated Fatty Liver Disease
inferred← citeshttps://doi.org/10.1002/advs.202002273openalex-snapshot
The Nuclear Orphan Receptor NR2F6 Promotes Hepatic Steatosis through Upregulation of Fatty Acid Transporter CD36
inferred← citeshttps://doi.org/10.1002/biof.2001openalex-snapshot
Advances in screening, synthesis, modification, and biomedical applications of peptides and peptide aptamers
inferred← citeshttps://doi.org/10.1002/bmc.70040openalex-snapshot
Mechanism of Bile‐Processed Coptidis Rhizoma in the Treatment of Type 2 Diabetes Mellitus in Rats Based on Dissolution Kinetics and Untargeted Metabolomics
inferred← citeshttps://doi.org/10.1002/brb3.71416openalex-snapshot
ASL/ALT Ratio in Familial and Sporadic Parkinson's Disease: Insights From Cross‐Sectional Logistic Analysis
inferred← citeshttps://doi.org/10.1002/cbdv.202200146openalex-snapshot
Dihydroflavonoids as Bioactive Components of Penthorum chinense, a Miao Ethnomedicine, against NAFLD through Bile Acid Metabolism Pathway
inferred← citeshttps://doi.org/10.1002/edm2.163openalex-snapshot
Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review
inferred← citeshttps://doi.org/10.1002/hep.31806openalex-snapshot
Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1002/hep.31822openalex-snapshot
Increased Adipose Tissue Fibrogenesis, Not Impaired Expandability, Is Associated With Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1002/hep.32072openalex-snapshot
Nonalcoholic Fatty Liver Disease and Cardiac Remodeling Risk: Pathophysiological Mechanisms and Clinical Implications
inferred← citeshttps://doi.org/10.1002/jcla.23602openalex-snapshot
Ferritin as a key risk factor for nonalcoholic fatty liver disease in children with obesity
inferred← citeshttps://doi.org/10.1002/mnfr.202200525openalex-snapshot
Comparative Lipidomics and Metabolomics Reveal the Underlying Mechanisms of Taurine in the Alleviation of Nonalcoholic Fatty Liver Disease Using the Aged Laying Hen Model
inferred← citeshttps://doi.org/10.1002/mrc.70017openalex-snapshot
NMR‐Based Metabolomics Reveals Metabolic Pathway Disruptions and Potential Biomarkers for Fibrosis
inferred← citeshttps://doi.org/10.1002/nbm.5290openalex-snapshot
Fatty acid composition evaluation of abdominal adipose tissue using chemical shiftencoded MRI: Association with diabetes
inferred← citeshttps://doi.org/10.1002/prp2.700openalex-snapshot
Dexmedetomidine ameliorates high‐fat diet‐induced nonalcoholic fatty liver disease by targeting SCD1 in obesity mice
inferred← citeshttps://doi.org/10.1002/ptr.8443openalex-snapshot
Dihydrotanshinone I Attenuates Diet‐Induced Nonalcoholic Fatty Liver Disease via Up‐Regulation of IRG1
inferred← citeshttps://doi.org/10.1002/smmd.20220010openalex-snapshot
Recent advances in liver‐on‐chips: Design, fabrication, and applications
inferred← citeshttps://doi.org/10.1002/ueg2.12513openalex-snapshot
Predictors of controlled attenuation parameter in metabolic dysfunction
inferred← citeshttps://doi.org/10.1007/5584_2020_532openalex-snapshot
Non-alcoholic Fatty Liver Disease and Diabetes Mellitus
inferred← citeshttps://doi.org/10.1007/978-3-031-33548-8_13openalex-snapshot
Pathophysiology and Risk Stratification in Cardiovascular Diseases and NAFLD
inferred← citeshttps://doi.org/10.1007/978-981-16-4525-9_5openalex-snapshot
Exercise-Mediated Autophagy and Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1007/s00011-023-01776-2openalex-snapshot
Pirfenidone ameliorates liver steatosis by targeting the STAT3-SCD1 axis
inferred← citeshttps://doi.org/10.1007/s00109-022-02282-4openalex-snapshot
Recent updates on targeting the molecular mediators of NAFLD
inferred← citeshttps://doi.org/10.1007/s00228-023-03586-1openalex-snapshot
The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review
inferred← citeshttps://doi.org/10.1007/s00394-021-02772-0openalex-snapshot
The effects of fish oil plus vitamin D3 intervention on non-alcoholic fatty liver disease: a randomized controlled trial
inferred← citeshttps://doi.org/10.1007/s10787-021-00916-6openalex-snapshot
The effects of metformin, pioglitazone, exenatide and exercise on fatty liver in obese diabetic rats: the role of IRS-1 and SOCS-3 molecules
inferred← citeshttps://doi.org/10.1007/s11130-024-01262-yopenalex-snapshot
B-Type Trimeric Procyanidins Attenuate Nonalcoholic Hepatic Steatosis Through AMPK/mTOR Signaling Pathway in Oleic Acid-Induced HepG2 Cells and High-Fat Diet- Fed Zebrafish
inferred← citeshttps://doi.org/10.1007/s11154-025-09980-7openalex-snapshot
Targeted therapeutic strategies as alternative and sustainable treatment options for obesity-induced steatohepatitis
inferred← citeshttps://doi.org/10.1007/s11684-021-0862-5openalex-snapshot
Mechanism of insulin resistance in obesity: a role of ATP
inferred← citeshttps://doi.org/10.1007/s11883-023-01146-7openalex-snapshot
Impacts of Non-alcoholic Fatty Liver Disease on Acute Coronary Syndrome: Evidence and Controversies
inferred← citeshttps://doi.org/10.1007/s11892-020-01349-1openalex-snapshot
Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1007/s12020-023-03522-4openalex-snapshot
MiR-143-3p/FNDC5 axis: a novel regulator of insulin sensitivity
inferred← citeshttps://doi.org/10.1007/s12072-020-10121-2openalex-snapshot
How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?
inferred← citeshttps://doi.org/10.1007/s12072-021-10242-2openalex-snapshot
First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients
inferred← citeshttps://doi.org/10.1007/s12072-022-10414-8openalex-snapshot
The clinical implications of pre-liver transplant diabetes on post-liver transplant outcomes in patients with NASH: analysis of the UNOS database
inferred← citeshttps://doi.org/10.1007/s12072-025-10924-1openalex-snapshot
Comparison of diagnostic criteria for fatty liver disease in assessing cardiac dysfunction: a cross-sectional study
inferred← citeshttps://doi.org/10.1007/s13410-020-00879-4openalex-snapshot
GLP1 agonists beyond glycemic control—redefining their role
inferred← citeshttps://doi.org/10.1016/b978-0-12-821232-5.00023-9openalex-snapshot
Immune dysregulation in nonalcoholic steatohepatitis
inferred← citeshttps://doi.org/10.1016/b978-0-12-821617-0.00011-5openalex-snapshot
Understanding human diet, disease, and insulin resistance: scientific and evolutionary perspectives
inferred← citeshttps://doi.org/10.1016/b978-0-323-91707-0.00005-xopenalex-snapshot
Syndromes of severe insulin resistance: lessons from nature
inferred← citeshttps://doi.org/10.1016/j.abb.2025.110558openalex-snapshot
Nicotinamide N-methyltransferase in non-alcoholic fatty liver disease: Mechanistic insights and emerging therapeutic strategies
inferred← citeshttps://doi.org/10.1016/j.amjmed.2020.01.007openalex-snapshot
Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?
inferred← citeshttps://doi.org/10.1016/j.aohep.2020.06.009openalex-snapshot
Hepatic transcriptome signature correlated with HOMA-IR explains early nonalcoholic fatty liver disease pathogenesis
inferred← citeshttps://doi.org/10.1016/j.aohep.2020.09.006openalex-snapshot
Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1016/j.apsb.2021.12.012openalex-snapshot
Nuciferine protects against high-fat diet-induced hepatic steatosis and insulin resistance via activating TFEB-mediated autophagy–lysosomal pathway
inferred← citeshttps://doi.org/10.1016/j.aquatox.2026.107713openalex-snapshot
Hepatic toxicity induced by exposure to glyphosate/aminomethylphosphonic acid and oxytetracycline alone or in combination in zebrafish: A novel mechanism of the gut-liver axis
inferred← citeshttps://doi.org/10.1016/j.archger.2025.105813openalex-snapshot
Effects of the triglyceride-glucose index on non-alcoholic fatty liver disease: Causal evidence from longitudinal cohort studies
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2022.07.010openalex-snapshot
Impact of NAFLD and its pharmacotherapy on lipid profile and CVD
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2025.120557openalex-snapshot
Fatty liver-index, systemic inflammation and cardiovascular mortality. Results from the LURIC study
inferred← citeshttps://doi.org/10.1016/j.bbalip.2019.05.016openalex-snapshot
Turnover of bile acids in liver, serum and caecal content by high-fat diet feeding affects hepatic steatosis in rats
inferred← citeshttps://doi.org/10.1016/j.bbrc.2022.02.033openalex-snapshot
Inulin activates FXR-FGF15 signaling and further increases bile acids excretion in non-alcoholic fatty liver disease mice
inferred← citeshttps://doi.org/10.1016/j.bbrc.2022.09.099openalex-snapshot
Vaccarin improves insulin sensitivity and glucose uptake in diet-induced obese mice via activation of GPR120-PI3K/AKT/GLUT4 pathway
inferred← citeshttps://doi.org/10.1016/j.bbrc.2022.12.014openalex-snapshot
The natural flavone acacetin protects against high-fat diet-induced lipid accumulation in the liver via the endoplasmic reticulum stress/ferroptosis pathway
inferred← citeshttps://doi.org/10.1016/j.bcp.2025.116957openalex-snapshot
OTUB1 enhances fatty acid oxidation in APAP-induced liver injury by mediating ACSL5 deubiquitination
inferred← citeshttps://doi.org/10.1016/j.bcp.2026.117989openalex-snapshot
The therapeutic role of natural compounds mediated through Nrf2 in metabolic dysfunction-associated steatotic liver disease
inferred← citeshttps://doi.org/10.1016/j.bioorg.2020.104262openalex-snapshot
Design, synthesis and structure-activity relationship studies of novel partial FXR agonists for the treatment of fatty liver
inferred← citeshttps://doi.org/10.1016/j.biopha.2021.112404openalex-snapshot
Carminic acid mitigates fructose-triggered hepatic steatosis by inhibition of oxidative stress and inflammatory reaction
inferred← citeshttps://doi.org/10.1016/j.biopha.2021.112441openalex-snapshot
SP-1154, a novel synthetic TGF-β inhibitor, alleviates obesity and hepatic steatosis in high-fat diet-induced mice
inferred← citeshttps://doi.org/10.1016/j.biopha.2022.113374openalex-snapshot
An overview of ferroptosis in non-alcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1016/j.biopha.2022.113577openalex-snapshot
A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR)
inferred← citeshttps://doi.org/10.1016/j.biopha.2023.115464openalex-snapshot
Luteolin as a potential hepatoprotective drug: Molecular mechanisms and treatment strategies
inferred← citeshttps://doi.org/10.1016/j.biopha.2023.115519openalex-snapshot
Acetylation in pathogenesis: Revealing emerging mechanisms and therapeutic prospects
inferred← citeshttps://doi.org/10.1016/j.biopha.2025.118723openalex-snapshot
Relationship between hepatic lipid accumulation and type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.1016/j.bj.2023.100625openalex-snapshot
Gut mycobiome in metabolic diseases: Mechanisms and clinical implication
inferred← citeshttps://doi.org/10.1016/j.cell.2021.04.015openalex-snapshot
Mechanisms and disease consequences of nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1016/j.celrep.2020.02.051openalex-snapshot
Multi-omics Analysis of the Intermittent Fasting Response in Mice Identifies an Unexpected Role for HNF4α
inferred← citeshttps://doi.org/10.1016/j.cgh.2021.04.037openalex-snapshot
Weight Change and the Development of Nonalcoholic Fatty Liver Disease in Metabolically Healthy Overweight Individuals
inferred← citeshttps://doi.org/10.1016/j.cgh.2021.09.023openalex-snapshot
Safety and Efficacy of Glucagon-like Peptide 1 Receptor Agonists in Patients With Cirrhosis
inferred← citeshttps://doi.org/10.1016/j.clinre.2020.05.018openalex-snapshot
Cytochrome P450 2E1 should not be neglected for acetaminophen-induced liver injury in metabolic diseases with altered insulin levels or glucose homeostasis
inferred← citeshttps://doi.org/10.1016/j.clinre.2023.102163openalex-snapshot
Poor cardiorespiratory fitness may be an indicator of more severe liver inflammation in non-alcoholic fatty liver disease patients
inferred← citeshttps://doi.org/10.1016/j.clinthera.2023.02.001openalex-snapshot
MicroRNAs as Biomarkers and Therapeutic Targets for Nonalcoholic Fatty Liver Disease: A Narrative Review
inferred← citeshttps://doi.org/10.1016/j.clnu.2020.11.037openalex-snapshot
A randomized controlled clinical trial comparing calcitriol versus cholecalciferol supplementation to reduce insulin resistance in patients with non-alcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1016/j.cmet.2023.07.011openalex-snapshot
Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis
inferred← citeshttps://doi.org/10.1016/j.cmet.2024.04.006openalex-snapshot
Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease
inferred← citeshttps://doi.org/10.1016/j.cpcardiol.2023.102065openalex-snapshot
Nonalcoholic Fatty Liver Disease (NAFLD) and Cardiovascular Risk: Is Imaging Helpful?
inferred← citeshttps://doi.org/10.1016/j.ecl.2022.06.007openalex-snapshot
Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1016/j.ejphar.2020.172913openalex-snapshot
Challenges and opportunities in drug development for nonalcoholic steatohepatitis
inferred← citeshttps://doi.org/10.1016/j.ejphar.2023.175744openalex-snapshot
Erianin alleviated liver steatosis by enhancing Nrf2-mediated VE-cadherin expression in vascular endothelium
inferred← citeshttps://doi.org/10.1016/j.ejphar.2023.175989openalex-snapshot
Human skin stem cell-derived hepatic cells as in vitro drug discovery model for insulin-driven de novo lipogenesis
inferred← citeshttps://doi.org/10.1016/j.ejphar.2023.176113openalex-snapshot
GW9662 ameliorates nonalcoholic steatohepatitis by inhibiting the PPARγ/CD36 pathway and altering the gut microbiota
inferred← citeshttps://doi.org/10.1016/j.envpol.2020.116304openalex-snapshot
Bisphenol F induces nonalcoholic fatty liver disease-like changes: Involvement of lysosome disorder in lipid droplet deposition
inferred← citeshttps://doi.org/10.1016/j.fbio.2025.106868openalex-snapshot
Polyphenol-enriched sorghum bran extract ameliorates high-fat-diet-induced skeletal muscle metabolic inflexibility by promoting mitochondrial function
inferred← citeshttps://doi.org/10.1016/j.foodres.2026.120973openalex-snapshot
AMPK activation and urea cycle enhancement mediate the protective effect of dietary leucine restriction in nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1016/j.freeradbiomed.2022.06.226openalex-snapshot
Nonalcoholic steatohepatitis and mechanisms by which it is ameliorated by activation of the CNC-bZIP transcription factor Nrf2
inferred← citeshttps://doi.org/10.1016/j.freeradbiomed.2023.04.001openalex-snapshot
A novel small molecule AdipoR2 agonist ameliorates experimental hepatic steatosis in hamsters and mice
inferred← citeshttps://doi.org/10.1016/j.freeradbiomed.2025.02.017openalex-snapshot
Regular exercise alleviates metabolic dysfunction-associated steatohepatitis through rescuing mitochondrial oxidative stress and dysfunction in liver
inferred← citeshttps://doi.org/10.1016/j.fufo.2025.100653openalex-snapshot
Black soldier fly larvae oil: A functional lipid that improves insulin sensitivity mainly by inhibiting the PPAR and MAPK signaling
inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2025.141660openalex-snapshot
Targeting regulation of lipid metabolism with polysaccharide of traditional Chinese medicine for the treatment of non-alcoholic fatty liver disease: A review
inferred← citeshttps://doi.org/10.1016/j.intimp.2021.107609openalex-snapshot
Neutrophil: An emerging player in the occurrence and progression of metabolic associated fatty liver disease
inferred← citeshttps://doi.org/10.1016/j.isci.2022.103859openalex-snapshot
Deletion of RNF186 expression suppresses diet-induced hepatic steatosis by regulating insulin activity
inferred← citeshttps://doi.org/10.1016/j.isci.2023.108692openalex-snapshot
Adipocyte hypertrophy associates with in vivo postprandial fatty acid metabolism and adipose single-cell transcriptional dynamics
inferred← citeshttps://doi.org/10.1016/j.isci.2024.108783openalex-snapshot
Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
inferred← citeshttps://doi.org/10.1016/j.jafr.2026.103254openalex-snapshot
Polysaccharide III from Polygonatum cyrtonema Hua alleviates diabetes-associated MASLD via PPAR pathway-mediated regulation of lipid metabolism and gut microbiota modulation
inferred← citeshttps://doi.org/10.1016/j.jaut.2023.103034openalex-snapshot
The role of faecal microbiota transplantation in chronic noncommunicable disorders
inferred← citeshttps://doi.org/10.1016/j.jbc.2022.101946openalex-snapshot
Leukemia inhibitory factor protects against liver steatosis in nonalcoholic fatty liver disease patients and obese mice
inferred← citeshttps://doi.org/10.1016/j.jbc.2023.104917openalex-snapshot
Hepatic protein kinase Cbeta deficiency mitigates late-onset obesity
inferred← citeshttps://doi.org/10.1016/j.jcmgh.2019.04.007openalex-snapshot
Metabolic Targets in Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1016/j.jcmgh.2020.10.006openalex-snapshot
S100A11 Promotes Liver Steatosis via FOXO1-Mediated Autophagy and Lipogenesis
inferred← citeshttps://doi.org/10.1016/j.jcmgh.2022.01.006openalex-snapshot
Inflammation: The Straw That Broke the NAFLD Liver!
inferred← citeshttps://doi.org/10.1016/j.jcmgh.2023.08.001openalex-snapshot
Escherichia coli Promotes Endothelial to Mesenchymal Transformation of Liver Sinusoidal Endothelial Cells and Exacerbates Nonalcoholic Fatty Liver Disease Via Its Flagellin
inferred← citeshttps://doi.org/10.1016/j.jdiacomp.2020.107706openalex-snapshot
Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes
inferred← citeshttps://doi.org/10.1016/j.jep.2025.119937openalex-snapshot
Gan-tang-yi decoction improves hepatic insulin resistance through activation of IRS2/PI3K/Akt pathway and inhibition of AGEs/RAGE pathway in cirrhotic rats
inferred← citeshttps://doi.org/10.1016/j.jff.2024.106234openalex-snapshot
Marine algae oils from Phaeodactylum tricornutum and Laminaria japonica alleviate obesity, insulin resistance, and gut microbiota dysbiosis in high-fat diet-fed mice
inferred← citeshttps://doi.org/10.1016/j.jff.2025.106946openalex-snapshot
Chitosan lactate mitigates metabolic-associated fatty liver disease via TGR5-mediated anti-inflammatory mechanisms and the gut-hepatic-bile acid axis
inferred← citeshttps://doi.org/10.1016/j.jgr.2023.11.003openalex-snapshot
Pharmacological potential of ginseng and ginsenosides in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
inferred← citeshttps://doi.org/10.1016/j.jhep.2021.06.030openalex-snapshot
Polyploidy control in hepatic health and disease
inferred← citeshttps://doi.org/10.1016/j.jhep.2023.07.034openalex-snapshot
FXR agonists in NASH treatment
inferred← citeshttps://doi.org/10.1016/j.jhep.2024.08.012openalex-snapshot
Dysglycemia and liver lipid content determine the relationship of insulin resistance with hepatic OXPHOS capacity in obesity
inferred← citeshttps://doi.org/10.1016/j.jhep.2024.08.024openalex-snapshot
Frailty and risk of metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases
inferred← citeshttps://doi.org/10.1016/j.jhepr.2019.07.002openalex-snapshot
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
inferred← citeshttps://doi.org/10.1016/j.jhepr.2023.100791openalex-snapshot
A machine learning-based classification of adult-onset diabetes identifies patients at risk of liver-related complications
inferred← citeshttps://doi.org/10.1016/j.jlr.2022.100318openalex-snapshot
Six-Transmembrane Epithelial Antigen of Prostate 3 Promotes Hepatic Insulin Resistance and Steatosis
inferred← citeshttps://doi.org/10.1016/j.jlr.2023.100363openalex-snapshot
Insulin dysregulation drives mitochondrial cholesterol metabolite accumulation: initiating hepatic toxicity in nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1016/j.jlr.2024.100580openalex-snapshot
Similar insulin regulation of splanchnic FFA and VLDL-TG in men with nonalcoholic hepatic steatosis and steatohepatitis
inferred← citeshttps://doi.org/10.1016/j.jlr.2025.100921openalex-snapshot
Asprosin as a regulator of hepatic lipogenesis and its association with hepatic steatosis
inferred← citeshttps://doi.org/10.1016/j.jnutbio.2021.108602openalex-snapshot
Tomatidine ameliorates obesity-induced nonalcoholic fatty liver disease in mice
inferred← citeshttps://doi.org/10.1016/j.jnutbio.2021.108751openalex-snapshot
Consumption of soybean or olive oil at recommended concentrations increased the intestinal microbiota diversity and insulin sensitivity and prevented fatty liver compared to the effects of coconut oil
inferred← citeshttps://doi.org/10.1016/j.jnutbio.2026.110452openalex-snapshot
Nobiletin ameliorates hepatic insulin resistance by modulating the gut–liver axis
inferred← citeshttps://doi.org/10.1016/j.lfs.2021.119314openalex-snapshot
Exercise improves lipid droplet metabolism disorder through activation of AMPK-mediated lipophagy in NAFLD
inferred← citeshttps://doi.org/10.1016/j.livres.2021.03.004openalex-snapshot
Vitamins and non-alcoholic fatty liver disease: A molecular insight
inferred← citeshttps://doi.org/10.1016/j.mce.2024.112404openalex-snapshot
Female C57BL/6 mice exhibit protection against nonalcoholic fatty liver disease and diabesity accompanied by differential regulation of hepatic lipocalin prostaglandin D2 synthase
inferred← citeshttps://doi.org/10.1016/j.metabol.2020.154454openalex-snapshot
Functions of amyloid precursor protein in metabolic diseases
inferred← citeshttps://doi.org/10.1016/j.metabol.2020.154457openalex-snapshot
Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression
inferred← citeshttps://doi.org/10.1016/j.metabol.2021.154844openalex-snapshot
Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1016/j.metabol.2022.155264openalex-snapshot
Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives
inferred← citeshttps://doi.org/10.1016/j.metabol.2023.155679openalex-snapshot
Olfactomedin 4 deletion exacerbates nonalcoholic fatty liver disease through P62-dependent mitophagy in mice
inferred← citeshttps://doi.org/10.1016/j.metabol.2023.155721openalex-snapshot
Can liquid biopsies for MASH help increase the penetration of metabolic surgery? A narrative review
inferred← citeshttps://doi.org/10.1016/j.metop.2021.100149openalex-snapshot
Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD)
inferred← citeshttps://doi.org/10.1016/j.molmet.2021.101363openalex-snapshot
A novel peroxisome proliferator-activated receptor gamma ligand improves insulin sensitivity and promotes browning of white adipose tissue in obese mice
inferred← citeshttps://doi.org/10.1016/j.molmet.2022.101644openalex-snapshot
Repression of the iron exporter ferroportin may contribute to hepatocyte iron overload in individuals with type 2 diabetes
inferred← citeshttps://doi.org/10.1016/j.numecd.2021.06.023openalex-snapshot
Relationship between alcohol consumption and insulin resistance measured using the homeostatic model assessment for insulin resistance: A retrospective cohort study of 280,194 people
inferred← citeshttps://doi.org/10.1016/j.nutos.2024.05.014openalex-snapshot
Effect of synbiotic supplementation on liver function, metabolic profile and gut microbiota in non-alcoholic fatty liver disease (NAFLD): A meta-analysis of randomized controlled trials
inferred← citeshttps://doi.org/10.1016/j.nutres.2025.03.004openalex-snapshot
High salt diet causally increases metabolic dysfunction-associated steatotic liver disease risk: A bidirectional mendelian randomization study
inferred← citeshttps://doi.org/10.1016/j.omtn.2024.102184openalex-snapshot
Oligonucleotide therapies for nonalcoholic steatohepatitis
inferred← citeshttps://doi.org/10.1016/j.peptides.2021.170597openalex-snapshot
A synthetic peptide AWRK6 ameliorates metabolic associated fatty liver disease: involvement of lipid and glucose homeostasis
inferred← citeshttps://doi.org/10.1016/j.pharma.2024.02.005openalex-snapshot
Anthocyanins: Potential phytochemical candidates for the amelioration of non-alcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1016/j.pharmthera.2024.108699openalex-snapshot
Tissue-specific activation of insulin signaling as a potential target for obesity-related metabolic disorders
inferred← citeshttps://doi.org/10.1016/j.phrs.2020.105035openalex-snapshot
ZLY032, the first-in-class dual FFA1/PPARδ agonist, improves glucolipid metabolism and alleviates hepatic fibrosis
inferred← citeshttps://doi.org/10.1016/j.phrs.2021.105484openalex-snapshot
Epigenetics in NAFLD/NASH: Targets and therapy
inferred← citeshttps://doi.org/10.1016/j.phymed.2023.155005openalex-snapshot
Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis
inferred← citeshttps://doi.org/10.1016/j.phyplu.2025.100814openalex-snapshot
Antidiabetic potential of Phaleria macrocarpa fruit liquid CO₂ extract: Bioactivity, cytotoxicity, phytochemicals and molecular targets
inferred← citeshttps://doi.org/10.1016/j.psj.2022.102428openalex-snapshot
Lipidomics analysis reveals new insights into the goose fatty liver formation
inferred← citeshttps://doi.org/10.1016/j.surg.2025.109966openalex-snapshot
Characterizing liver disease in patients undergoing bariatric surgery: Prevalence and outcomes of 180,544 cases
inferred← citeshttps://doi.org/10.1016/j.tem.2019.05.007openalex-snapshot
Going Back to the Biology of FGF21: New Insights
inferred← citeshttps://doi.org/10.1016/j.xcrm.2021.100474openalex-snapshot
Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study
inferred← citeshttps://doi.org/10.1016/j.yjmcc.2021.10.007openalex-snapshot
NAFLD as a continuous driver in the whole spectrum of vascular disease
inferred← citeshttps://doi.org/10.1021/acs.biochem.2c00624openalex-snapshot
Effects of UBE3A on Cell and Liver Metabolism through the Ubiquitination of PDHA1 and ACAT1
inferred← citeshttps://doi.org/10.1021/acs.est.5c15793openalex-snapshot
Pollutant–Diet Interactions Drive Distinct Mechanisms of Tetrabromobisphenol A-Induced Hepatic Insulin Resistance in Zebrafish
inferred← citeshttps://doi.org/10.1021/acs.jafc.2c00641openalex-snapshot
Pterostilbene and Its Derivative 3′-Hydroxypterostilbene Ameliorated Nonalcoholic Fatty Liver Disease Through Synergistic Modulation of the Gut Microbiota and SIRT1/AMPK Signaling Pathway
inferred← citeshttps://doi.org/10.1038/s41366-025-01774-wopenalex-snapshot
The effect of aldafermin expressing-Escherichia coli Nissle 1917 along with dietary change on visceral adipose tissue in MASLD mouse model
inferred← citeshttps://doi.org/10.1038/s41387-020-0114-9openalex-snapshot
Reducing endogenous insulin is linked with protection against hepatic steatosis in mice
inferred← citeshttps://doi.org/10.1038/s41392-022-01073-0openalex-snapshot
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
inferred← citeshttps://doi.org/10.1038/s41418-025-01444-4openalex-snapshot
USP25 directly interacts with and deubiquitinates PPARα to increase PPARα stability in hepatocytes and attenuate high-fat diet-induced MASLD in mice
inferred← citeshttps://doi.org/10.1038/s41430-021-01044-8openalex-snapshot
Role of high-salt diet in non-alcoholic fatty liver disease: a mini-review of the evidence
inferred← citeshttps://doi.org/10.1038/s41467-022-31812-4openalex-snapshot
Loss of immunity-related GTPase GM4951 leads to nonalcoholic fatty liver disease without obesity
inferred← citeshttps://doi.org/10.1038/s41467-024-53002-0openalex-snapshot
CHIP ameliorates nonalcoholic fatty liver disease via promoting K63- and K27-linked STX17 ubiquitination to facilitate autophagosome-lysosome fusion
inferred← citeshttps://doi.org/10.1038/s41598-020-72022-6openalex-snapshot
Maternal exercise conveys protection against NAFLD in the offspring via hepatic metabolic programming
inferred← citeshttps://doi.org/10.1038/s41598-022-10032-2openalex-snapshot
Association between physical activity and insulin resistance using the homeostatic model assessment for insulin resistance independent of waist circumference
inferred← citeshttps://doi.org/10.1038/s41598-022-11950-xopenalex-snapshot
Additional treatment of vitamin D for improvement of insulin resistance in non-alcoholic fatty liver disease patients: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1038/s41598-022-16119-0openalex-snapshot
Therapeutic effects of isosteviol sodium on non-alcoholic fatty liver disease by regulating autophagy via Sirt1/AMPK pathway
inferred← citeshttps://doi.org/10.1038/s41598-022-16688-0openalex-snapshot
Xanthine oxidoreductase activity is correlated with hepatic steatosis
inferred← citeshttps://doi.org/10.1038/s41598-023-35001-1openalex-snapshot
Associations of alanine aminotransferase/aspartate aminotransferase with insulin resistance and β-cell function in women
inferred← citeshttps://doi.org/10.1038/s41598-023-47269-4openalex-snapshot
Markers of insulin resistance associated with non-alcoholic fatty liver disease in non-diabetic population
inferred← citeshttps://doi.org/10.1038/s41598-024-67728-wopenalex-snapshot
Association of Life’s Essential 8 with metabolic dysfunction-associated steatotic liver disease (MASLD), a cross-sectional study from the NHANES 2003–2018
inferred← citeshttps://doi.org/10.1038/s41598-024-69411-6openalex-snapshot
Baseline and change in serum lipid and uric acid level over time and incident of nonalcoholic fatty liver disease (NAFLD) in Chinese adults
inferred← citeshttps://doi.org/10.1038/s41598-024-71608-8openalex-snapshot
Nonlinear relationship between the triglyceride–glucose index and alanine aminotransferase in children with short stature
inferred← citeshttps://doi.org/10.1038/s41598-024-83013-2openalex-snapshot
Association between the ratio of serum uric acid to high-density lipoprotein cholesterol and liver fat content: evidence from a Chinese health examination dataset
inferred← citeshttps://doi.org/10.1038/s41598-025-10765-wopenalex-snapshot
Nonlinear relationship between body fat percentage and NAFLD mediated by METS-IR: threshold effects and subgroup differences
inferred← citeshttps://doi.org/10.1038/s41598-025-18919-6openalex-snapshot
BMI mediates the association of CALLY index with liver steatosis and fibrosis
inferred← citeshttps://doi.org/10.1038/s41598-025-87871-2openalex-snapshot
Characteristics of different lipid droplet-mitochondrial contacts patterns during lipid droplet metabolism in T2DM-induced MASLD
inferred← citeshttps://doi.org/10.1038/s41598-026-46378-0openalex-snapshot
The association of TyG-BMI with MAFLD and liver fibrosis: a cross-sectional study
inferred← citeshttps://doi.org/10.1038/s41598-026-54757-wopenalex-snapshot
Development of surfactin-based nanocarrier for targeted doxorubicin delivery
inferred← citeshttps://doi.org/10.1038/s42255-026-01507-xopenalex-snapshot
Revitalizing p-GSK-3β via cysteine sulfenylation promotes hepatic insulin resistance by differentially regulating glycogenesis and gluconeogenesis
inferred← citeshttps://doi.org/10.1038/s43587-024-00694-0openalex-snapshot
Aged bone marrow macrophages drive systemic aging and age-related dysfunction via extracellular vesicle-mediated induction of paracrine senescence
inferred← citeshttps://doi.org/10.1038/s44355-025-00042-yopenalex-snapshot
Adrenergic G protein-coupled receptors in liver physiology and pathology: research advances and clinical implications
inferred← citeshttps://doi.org/10.1039/d2fo00081dopenalex-snapshot
Coffee peel extracts ameliorate non-alcoholic fatty liver disease via a fibroblast growth factor 21–adiponectin signaling pathway
inferred← citeshttps://doi.org/10.1039/d2fo02774gopenalex-snapshot
A UPLC-Q-TOF/MS and network pharmacology method to explore the mechanism of Anhua fuzhuan tea intervention in nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1039/d3fo03572gopenalex-snapshot
Hepatoprotective efficacy and interventional mechanism of the panaxadiol saponin component in high-fat diet-induced NAFLD mice
inferred← citeshttps://doi.org/10.1039/d5fo02448jopenalex-snapshot
Association of fish oil supplementation with risk of incident severe non-alcoholic fatty liver disease: a prospective study of 488 888 individuals
inferred← citeshttps://doi.org/10.1055/a-1510-8896openalex-snapshot
Hepatic-Metabolite-Based Intermittent Fasting Enables a Sustained Reduction in Insulin Resistance in Type 2 Diabetes and Metabolic Syndrome
inferred← citeshttps://doi.org/10.1055/a-2338-9261openalex-snapshot
Inflammation in Steatotic Liver Diseases: Pathogenesis and Therapeutic Targets
inferred← citeshttps://doi.org/10.1055/a-2691-0442openalex-snapshot
Association of Body Composition with Insulin Resistance in a Middle-Aged Population
inferred← citeshttps://doi.org/10.1055/a-2720-5290openalex-snapshot
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Non-Alcoholic Fatty Liver Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
inferred← citeshttps://doi.org/10.1055/s-0041-1723751openalex-snapshot
Effects of Mediterranean Diet in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials
inferred← citeshttps://doi.org/10.1080/09581596.2026.2664251openalex-snapshot
Association between triglyceride-glucose-related indices and the prevalence of MAFLD/MASLD and hepatic fibrosis in American adults: an analysis of NHANES data
inferred← citeshttps://doi.org/10.1080/10408398.2022.2062589openalex-snapshot
Can omega-3 fatty acids be beneficial in pediatric NAFLD? A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1080/14728222.2020.1728742openalex-snapshot
Emerging therapeutic targets for NASH: key innovations at the preclinical level
inferred← citeshttps://doi.org/10.1080/17474124.2019.1649981openalex-snapshot
Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations
inferred← citeshttps://doi.org/10.1080/19490976.2024.2351620openalex-snapshot
Cultivated Enterococcus faecium B6 from children with obesity promotes nonalcoholic fatty liver disease by the bioactive metabolite tyramine
inferred← citeshttps://doi.org/10.1089/jir.2023.0162openalex-snapshot
Molecular Insights of Nonalcoholic Fatty Liver Disease Pathogenesis
inferred← citeshttps://doi.org/10.1093/jn/nxaa032openalex-snapshot
One-Carbon Metabolism in Fatty Liver Disease and Fibrosis: One-Carbon to Rule Them All
inferred← citeshttps://doi.org/10.1093/jn/nxaa410openalex-snapshot
Dietary Fruit and Vegetable Supplementation Suppresses Diet-Induced Atherosclerosis in LDL Receptor Knockout Mice
inferred← citeshttps://doi.org/10.1096/fj.201901510rropenalex-snapshot
Palmitoylethanolamide counteracts hepatic metabolic inflexibility modulating mitochondrial function and efficiency in diet‐induced obese mice
inferred← citeshttps://doi.org/10.1097/cm9.0000000000002711openalex-snapshot
Interaction between mucus layer and gut microbiota in non-alcoholic fatty liver disease: Soil and seeds
inferred← citeshttps://doi.org/10.1097/crd.0000000000000850openalex-snapshot
Effects of Sympathetic Denervation in Metabolism Regulation: A Novel Approach for the Treatment of MASLD?
inferred← citeshttps://doi.org/10.1097/hc9.0000000000000263openalex-snapshot
The empirical dietary inflammatory pattern score and the risk of nonalcoholic fatty liver disease and cirrhosis
inferred← citeshttps://doi.org/10.1097/hc9.0000000000000582openalex-snapshot
Fasting intact insulin by mass spectrometry is associated with metabolic dysfunction–associated steatotic liver disease in youth
inferred← citeshttps://doi.org/10.1097/hep.0000000000000185openalex-snapshot
Antagonizing apolipoprotein J chaperone promotes proteasomal degradation of mTOR and relieves hepatic lipid deposition
inferred← citeshttps://doi.org/10.1097/hjh.0000000000002279openalex-snapshot
Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient
showing the first 200 of 541 · page through all 541
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.